| Detailed information |
|---|
| CancerLivER ID | 2546 |
| Biomarker | HLA-DR |
| Biomarker Name/Symbol (given in Publication) | HLA-DR |
| Biomolecule | Protein and RNAs |
| Subject | Human |
| Degree of Validity | Prognostic marker for detection of early intrahepatic recurrence of HCC and validated on independent dataset |
| Experimental Condition | Intrahepatic recurrence v/s Non-recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC with early IHR vs. HCC without recurrence (with Fiser ratio 1.56) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15688398 |
| Type of Biomarker | Prognostic |
| Pathway | CXCR4-mediated signaling events and Translocation of ZAP-70 to Immunological synapse |
| Cohort | Training dataset: 33 HCC patients containing12 HCCs with early IHR (intrahepatic recurrence) and 21 HCCs with nonrecurrence; validation dataset:27 blinded HCC |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Intrahepatic recurrence v/s Non-recurrence |
| Year of Publication | 2005 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT03203837,NCT01974661 |